Liquidia Settles All Litigation With United Therapeutics for $380.7 Million, Securing Continued Access to YUTREPIA
YUTREPIA remains on the market for pulmonary arterial hypertension.
/ 9 items
#UTHR↓
United Therapeutics Wins Patent Case Against Liquidia’s Yutrepia
A Delaware judge found Liquidia’s Yutrepia infringes United Therapeutics’ PH-ILD patent. Final judgment is next.
Roivant Advances Mosliciguat to Phase 3 After Strongest PVR Reduction Yet in PH-ILD
Mosliciguat cut PVR 56.3% vs placebo in Phase 2 PH-ILD, improved 6-minute walk, and advanced to Phase 3. Shares jumped on the data.
United Therapeutics Acquires Thymmune Therapeutics for $300M to Advance Thymus-Based Regenerative Therapies
The deal accelerates United Therapeutics’ pipeline in immune restoration and transplant tolerance.
Liquidia Gets Bullish Signal from Hikma vs Amarin Ruling
Raymond James reiterates Strong Buy rating and $68 target on Liquidia after the Supreme Court’s positive Hikma v. Amarin decision.
Game-Changer for IPF: Inhaled Tyvaso Preserves Lung Function in Major TETON-1 Study
The United Therapeutics TETON-1 trial shows that inhaled Tyvaso preserves lung function by 130 mL versus placebo and reduces disease progression. Positive results were seen across all patient groups, with an FDA filing planned for this summer.